

DAFTAR PUSTAKA

- Andayani TM. 2013. Farmakoekonomi Prinsip & Metodologi. Edisi pertama. Yogyakarta: Bursa Ilmu
- Anderson PL, Yager J, Fletcher CV. 2020. Human Immunodeficiency Virus Infection. Dalam DiPiro JT, editor. Pharmacotherapy A Pathophysiologic Approach. 11th ed. New York: McGrawHill. hal. 6171 - 6273.
- Argyo D, Murti B, Zunariyah S. 2021. HIV/AIDS treatment funding system to support the people affected by HIV/AIDS in Surakarta, Indonesia. Journal of social aspects of HIV/AIDS 18(1):1-16, <https://doi.org/10.1080/17290376.2020.1858946>. [disitasi 10 Juni 2023]
- Arthurs E, Ward T, Darlington O, Sugrue D, Martin AA, Cartier SE, Lee A, Becker DL, Punekar YS, McEwan P. 2018. Dolutegravir and Rilpivirine to Treat Virologically Suppressed Adults Living with HIV-1: A Canadian Cost-Utility Analysis. Value in health, 21 (supplement 1). hal. S9-S10, <https://doi.org/10.1016/j.jval.2018.04.044>. [disitasi 09 Agustus 2023]
- Austin SB, Gordon AR, Ziyadeh NJ, Charlton BM, Katz-Wise SL, Samnaliev M. 2017. Stigma and health-related quality of life in sexual minorities. Am J Prev Med, 53(4), pp. 559-566. <http://doi:10.1016/j.amepre.2017.05.007>. [disitasi 27 Juli 2023]
- Badan Narkotika Nasional Republik Indonesia. 2021. Survey Nasional Penyalahgunaan Narkoba 2021. Jakarta: Badan Narkotika Nasional, Pusat Penelitian, Data dan Informasi, <https://ppid.bnn.go.id/konten/unggahahan/2020/10/SURVEI-NASIONALPENYALAHGUNAAN-NARKOBA-TAHUN-2021.pdf>. [disitasi 08 Juni 2023]
- Belay YB, Ali EE, Chung KY, Gebretekle GB, Sander B. 2021. Cost Utility Analysis of Dolutegravir versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia. Pharmacoeconomics. Mei; 5:654-664, <https://doi.org/10.1007/s41669-021-00275-6>. [disitasi 01 Juni 2023]
- Berger ML, Bingefors K, Hedblom EC, Pashos CL, Torrance GW. 2003. Biaya pelayanan kesehatan, kualitas dan hasil akhir : buku terminologi ISPOR Depok: ISPOR Indonesia Chapter.

- Bonk RJ. 2001. *Pharmacoeconomic in perspective : a primer on research, techniques and information* New York: Pharmaceutical Press.
- Bousmah MA, Nishimwe ML, Tovar-Sanchez T, Lantche, Wandji M, Mpoudi-Etame M, Maradan G, Omgba Bassega, Varloteaux Marie, Alice Montoyo, Charles Kouanfack, Eric Delaporte, Sylvie Boyer. 2021. Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial). *Pharmacoeconomics*. Maret; 39(3): 331-343, <https://link.springer.com/article/10.1007/s40273-020-00987-3>. [disitasi 09 Agustus 2023]
- Campos LN, Cesar CC, Guimaraes MDC. 2009. Quality of life among HIV infected patients in Brazil after initiation of treatment. *Clinics*. Juni; 64(9): 867-875, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC19759880/>. [disitasi 23 November 2022]
- Checa A, Castillo, Camacho M, Tapia W, Hernandez I, Teran E. 2020. Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador. *AIDS Research and Therapy* Juli; 17(47): 1 – 5, <https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-020-00303-1>. [disitasi 08 Juni 2023].
- Del Amo J. 2017. Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe (1996-2013): a collaborative cohort study. *Zurich Open Repository and Archive* 12(3), https://www.zora.uzh.ch/id/eprint/126827/1/00002030-900000000-97685_002.pdf: 253-262. [disitasi 05 Juni 2023].
- Devlin, Parkin, Janssen. 2020. *Methods for Analyzing and Reporting EQ-5D Data*. Gewerbestrasse: Springer Nature Switzerland AG.
- Dinas Kesehatan Pemerintah Provinsi Jambi, 2022. *Rencana strategis Dinas Kesehatan Provinsi Jambi 2021 - 2026*, Jambi. Available at: https://dinkes.jambiprov.go.id/all_renstra: Dinas Kesehatan Pemerintah Provinsi Jambi
- Doyle T. 2012. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. *Clin Infect Dis*. Maret; 54(5): 724-732, doi: 10.1093/cid/cir936. [disitasi 15 Juni 2023].
- Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. 2005. *Methods for the economic evaluation of health care programmes*. 3rd ed. Oxford: Oxford University Press.

- E. Ross , Mirowsky. 2010. Why Education Is the Key to Socioeconomic Differentials in Health. In E. Bird , Conrad P, M. Fremont , Timmermans, editor. Handbook of Medical Sociology. Nashville: Vanderbilt University Press. p. 33-52.
- Estevez MA, Porcuna , Suay , Monge , García F, Medina , et al. 2013. Quantification of viral loads lower than 50 copies per milliliter by use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 test, version 2.0, can predict the likelihood of subsequent virological rebound to >50 copies per milliliter. *Journal of Clinical Microbiology*. Mei; 51(5): 1555-1557, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647906/>. [disitasi 15 Juni 2023].
- Fitria N. 2020. Pedoman pembuatan review sistematik di bidang ekonomi kesehatan. Edisi pertama. Padang: Andalas University Press.
- Gerke O. 2020. Reporting Standards for a Bland–Altman Agreement Analysis: A Review of Methodological Reviews. *Diagnostics*. Mei; 10(334): 1-17, doi:10.3390/diagnostics10050334. [disitasi 08 Juni 2023].
- Gubernur Jambi, 2022. Keputusan Gubernur Jambi nomor 1047/KEP.GUB/DISNAKERTRANS-3.3/2022, Jambi. <https://paralegal.id/peraturan/keputusan-gubernur-jambi-nomor-1047-kep-gub-disnakertrans-3-3-2022/>: Gubernur Jambi.
- Guillén SM, García Juan Emilio Losa, Berenguer Juan Berenguer, Sesmero José Manuel Martínez, Gomis Santiago Cenoz, Graefehain Ruth, Sánchez-Cambronero, David López, García Francisco Javier Parrondo. 2017. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain. *Farmacia Hospitalaria*, 41(5), hal. 601-610, <https://scielo.isciii.es/pdf/fh/v41n5/2171-8695-fh-41-05-00601.pdf>. [disitasi 12 Agustus 2023]
- Gulo W. 2005. Metodologi Penelitian. 4th ed. Hardiwati Y, editor. Jakarta: Gramedia.
- Handajani YS, Djoerban Z, Irawan H. 2012. Quality of life people living with HIV/AIDS : Outpatient in Kramat 128 Hospital Jakarta. *Acta Medica Indonesia - The Indonesian Journal of Internal Medicine*. Oktober; 44(4): 310-316, <https://www.researchgate.net/publication/234124106>. [disitasi 20 Oktober 2022].
- Handayani F, Fatwa Sari TD. 2017. Faktor yang memengaruhi kualitas hidup orang dengan HIV/AIDS di Kota Kupang. *Berita Kedokteran Masyarakat*. November; 33(11): 509-514, <https://jurnal.ugm.ac.id/bkm/article/view/25856>. [disitasi 05 Juni 2023].

- Handayani. 2017. Waspada epidemi HIV - AIDS di Indonesia. *Medical and health science journal*. Februari; 1(1): 1-8, <https://journal2.unusa.ac.id/index.php/MHSJ/article/download/610/540/1033>. [disitasi 08 November 2022].
- Hegdah HK, Fylkesnes KM, Sandoy IF. 2016. Sex Differences in HIV Prevalence Persist over Time : Evidence from 18 Countries in Sub-Saharan Africa. *PloS One*. Februari; 11(2): 1-17, <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0148502>. [disitasi 10 Juni 2023]
- IAPAC : International association of providers of AIDS care. 2021. Viral Load, <https://www.iapac.org/factsheet/viralload/#:~:text=A%20high%20HIV%20viral%20load,copies%20per%20milliliter%20of%20blood.> . [disitasi 15 Juni 2023].
- Izmi H, Nadrizal , Rahman AO. 2021. Perbedaan kualitas hidup orang dengan HIV/AIDS yang mendapatkan terapi Antiretroviral berdasarkan lama terapinya di Yayasan Kanti Sehati. *MEDIC*. April; 4(1): 227-240, <https://online-journal.unja.ac.id/medic/article/download/13499/11300>. [disitasi 11 Oktober 2022]
- Kementerian Kesehatan Republik Indonesia. 2006. Pedoman pelayanan kefarmasian untuk orang dengan HIV/AIDS (ODHA). Jakarta, <https://farmalkes.kemkes.go.id/unduh/pedoman-pelayanan-kefarmasian-untuk-orang-dengan-hiv-aids-odha/>. [disitasi 20 November 2022].
- Kementerian Kesehatan Republik Indonesia. 2011. Pedoman Nasional tatalaksana klinis, infeksi HIV dan terapi antiretroviral pada orang dewasa. Jakarta.
- Kementerian Kesehatan Republik Indonesia. 2013. Pedoman Penerapan Kajian Farmakoekonomi Sarnianto P, Fadia Z, Gusneliyenti E, editors. Jakarta.
- Kementerian Kesehatan Republik Indonesia. 2014. Panduan praktik klinis bagi dokter di fasilitas pelayanan kesehatan primer. Edisi revisi. Jakarta.
- Kementerian Kesehatan Republik Indonesia. 2014. Peraturan Menteri Kesehatan Republik Indonesia no.87 tahun 2014 tentang pedoman pengobatan antiretroviral.
- Kementerian Kesehatan Republik Indonesia. 2014. Peraturan Menteri Kesehatan nomor 28 tahun 2014 tentang Pedoman Pelaksanaan Jaminan Kesehatan Nasional. Jakarta.

- Kementerian Kesehatan Republik Indonesia. 2017. Kajian Nasional Respon HIV di bidang kesehatan Republik Indonesia, https://www.who.int/docs/defaultsource/searo/indonesia/non-who-publications/2017-hiv-country-review-indonesiabahasa.pdf?sfvrsn=6cca118_2. [disitasi 07 November 2022].
- Kementerian Kesehatan Republik Indonesia. 2019. Keputusan Menteri Kesehatan Republik Indonesia No.: HK.01.07/Menkes/90/2019 tentang Pedoman Nasional Pelayanan Kedokteran Tatalaksana HIV. Jakarta.
- Kementerian Kesehatan Republik Indonesia. 2020. Farmakologi terkait HIV dan PIMS. In Pelatihan jarak jauh akselerasi ARV dalam penanggulangan HIV/AIDS dan PIMS bagi tenaga kesehatan di FKTP dan FKTRL. Jakarta.
- Kementerian Kesehatan Republik Indonesia. 2020. Laporan pemodelan epidemi HIV 2020 : estimasi dan proyeksi HIV AIDS di Indonesia tahun 2019 - 2024. Jakarta, https://siha.kemkes.go.id/portal/files_upload/ESTIMASI_DAN_PROYEKSI_HIVAIDS_DI_INDONESIA_2015__2020.pdf. [disitasi 20 November 2022].
- Kementerian Kesehatan Republik Indonesia. 2021. Keputusan Menteri Kesehatan nomor HK.01.07/MENKES/5675/2021 tentang data penduduk sasaran program pembangunan kesehatan tahun 2021 – 2025. Jakarta, <https://www.kemkes.go.id/downloads/resources/download/info-terkini/KMK-No.-HK.01.07-MENKES-5675-2021-ttg-Data-Penduduk-Sasaran-Program-Pembangunan-Kesehatan-2021-2025-signed.pdf>. [disitasi 20 November 2022].
- Kementerian Kesehatan Republik Indonesia. 2022. Peraturan Menteri Kesehatan nomor 23 tahun 2022 tentang Penanggulangan Human Immunodeficiency Virus, Acquired Immunodeficiency syndrome dan Infeksi Menular Seksual. Peraturan Menteri Kesehatan. Jakarta.
- Kementerian Kesehatan Republik Indonesia. 2022. Profil Kesehatan Indonesia tahun 2021. Sibuea F, Hardhana B, Widiyanti W, editors. Jakarta.
- Khoiriyah SD, Lestari K. 2018. Review artikel : kajian farmakoekonomi yang mendasari pemilihan pengobatan di Indonesia. *Farmaka*. September; 16(3): 134-145, <https://jurnal.unpad.ac.id/farmaka/article/view/17435>. [disitasi 28 November 2022].
- Khumsaen, N., Aouf-por, W. & Thammachak, P., 2012. Factors influencing quality of life among people. *Journal of the Association of Nurses* in, 23(1), pp. 63-72. Available at : <https://www.sciencedirect.com/science/article/abs/pii/S1055329011000069?via%3Dihub>

- Kishiyama JL. 2014. Disorders of the immune system. In Hammer GD, McPhee SJ, editors. *Patophysiology of disease*. New York: Mc Graw Hill. p. 31-60.
- Kusuma H. 2016. Faktor-faktor yang mempengaruhi kualitas hidup pasien HIV/AIDS yang menjalani perawatan di RSUPN Cipto Mangunkusumo Jakarta. *Media Medika Muda*. Mei - Agustus; 1(2): 115-124, <https://ejournal2.undip.ac.id/index.php/mmm/article/view/2602/0>. [disitasi 02 November 2022].
- Lan VM. 2012. Virus imunodefisiensi manusia (HIV) dan sindrom imunodefisiensi didapat (AIDS). In Huriawati H, Natalia S, Wulansari P, Mahanani DA, editors. *Patofisiologi : konsep klinis proses-proses penyakit*. 6th ed. Jakarta: Penerbit buku kedokteran EGC. p. 224 - 245.
- Lianhong X, Desai MC. 2009. Pharmacokinetic enhancers for HIV drugs. *Curr Opin Investig Drugs*. Agustus; 10(8): 775-787, <https://pubmed.ncbi.nlm.nih.gov/19649922/>. [disitasi 28 November 2022].
- Liyonovitasari, Setyoningrum U. 2020. Gambaran Kualitas Hidup Orang dengan HIV/AIDS (ODHA). *Indonesian Journal of Nursing Research (IJNR)*. September; 3(2): 75-82, <https://jurnal.unw.ac.id/index.php/ijnr/article/view/907>. [disitasi 08 Juni 2023].
- M, Ahmad RA, Riyanto BS. 2017. Kualitas hidup orang dengan HIV/AIDS berdasarkan kriteria diagnosis dan faktor lain di Surakarta. *BKM Journal of Community Medicine and Public Health*. Maret; 33(3): 147-152, <https://jurnal.ugm.ac.id/bkm/article/view/12563/15697>. [disitasi 08 November 2022].
- Mannheimer SB MJTECMCCWAFG, Beirn T. 2015. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. *AIDS Care*. Januari; 17(1): 10-22, <https://www.tandfonline.com/doi/full/10.1080/09540120412331305098>. [disitasi 23 November 2022].
- Mrus , J. et al., 2005. Gender differences in health-related quality of life in patients with HIV/AIDS. *Quality of life research*, Volume 14, pp. 479–491, <https://doi.org/10.1007/s11136-004-4693-z>.
- Mutabazi-Mwesigire D, Katamba A, Martin F, Seeley J, Wu AW. 2015. Factors that affect quality of life among people living with HIV attending an Urban Clinic in Uganda : a cohort study. *PlosOne*, https://www.researchgate.net/publication/277781705_Factors_That_Affect_Quality_of_Life_among_People_Living_with_HIV_Attending_an_Urban_Clinic_in_Uganda_A_Cohort_Study. [disitasi 09 November 2022].

- NAM Publications. 2019. Dolutegravir recommended for all in new World Health Organization guidelines, <https://www.aidsmap.com/news/jul-2019/dolutegravir-recommended-all-new-world-health-organization-guidelines>. [disitasi 28 November 2022].
- National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention - CDC. 2016. Terms, Definitions, and Calculations Used in CDC HIV Surveillance Publications, <https://www.cdc.gov/hiv/pdf/statistics/systems/nhbs/cdc-hiv-terms-surveillance-publications-2014.pdf> . [disitasi 23 November 2022].
- Netuveli, G. & Blane, D., Maret 2008. Quality of life in older ages. *British Medical Bulletin*, 85(1), pp. 113-126, <https://doi.org/10.1093/bmb/ldn003>.
- Nojomi , M., Anbary , K. & Ranjbar, 2008. Health-Related Quality of Life in Patients with HIV/AIDS. *J Arch Iran Med*, 11(6), pp. 608-612, <https://pubmed.ncbi.nlm.nih.gov/18976030/>.
- Nyoto WA, Djauzi S, Djoerban Z, Prodjosudjadi W. 2007. Quality of life of HIV patiens and influential factors. *Acta Medica Indonesiana*. Januari - Maret; 39(1): 2-7, <https://www.inaactamedica.org/archives/2007/17297202.pdf>. [disitasi 08 November 2022].
- Oemar M, Janssen B. 2013. EQ-5D-5L Users guide, basic information on how to use the EQ-5D-5L instrument. https://www.unmc.edu/centric/_documents/EQ-5D5L.pdf . [disitasi 18 November 2022].
- Panel ahli penanggulangan HIV/AIDS dan IMS, 2020. Rekomendasi panel ahli penanggulangan HIV/AIDS dan IMS, Jakarta: Available at : https://hivaids-pimsindonesia.or.id/download/file/REKOMENDASI_PANEL_AHLI_HIV_DAN_IMS.pdf.
- Pardita DPY, Sudibia IK. 2014. Analisis dampak sosial, ekonomi dan psikologis penderita HIV/AIDS di Kota Denpasar. *Jurnal buletin studi ekonomi*. Agustus; 19(2) : 193-199, <https://ojs.unud.ac.id/index.php/bse/article/view/18814>. [disitasi 04 Juni 2023].
- Parondo, J., Moreno, S., Losa, JE., Berenguer, J., Martinez-Sesmero, JM., Cenoz-Gomis, S., Grasset, E. November 2015. Cost-Utility Analysis of Dolutegravir/Abacavir/Lamivudine (Dtg/Abc/3tc) as a Single Tablet Treatment of Naïve Hiv Infected Patientss. *Value in health*, 18(7): PA588-A589, DOI:<https://doi.org/10.1016/j.jval.2015.09.1507>. [disitasi 12 Agustus 2023]

- Pemerintah Republik Indonesia. 2003. Undang-undang no. 20 Tahun 2003. Jakarta. <https://peraturan.bpk.go.id/Home/Details/43920/uu-no-20-tahun-2003>. [disitasi 10 Juni 2023].
- Pradono, J., Hapsari, D. & Sari, P., 2009. Kualitas hidup penduduk Indonesia menurut International Classification of Functioning, disability and health (ICF) dan faktor-faktor yang mempengaruhinya. *Bulletin penelitian kesehatan*, pp. 1-10. Available at: <https://media.neliti.com/media/publications-test/67481-kualitas-hidup-penduduk-indonesia-menuru-7ae275b5.pdf>.
- Prayoga H, Ayuningtyas D. 2022. Pengukuran Kualitas Hidup Pasien HIV/AIDS di RSUD Pasar Rebo menggunakan Instrumen EQ-5D-5L. *Journals of Ners Community*. [Desember; 13(6): 827-833, <https://journal.unigres.ac.id/index.php/JNC/article/view/2423/1775>. [disitasi 06 Juni 2023]
- Price SA, Wilson LM. 2012. *Patofisiologi*. 6th ed. Hartanto H, Susi N, Wulansari P, Mahanani DA, editors. Jakarta: Penerbit Buku Kedokteran EGC.
- Public Health Agency of Canada. 2012. HIV Transmission risk : a summary of the evidence. <https://www.catie.ca/sites/default/files/HIV-TRANSMISSION-RISK-EN.pdf> . [disitasi 24 November 2022].
- Punekar, Y. S., Guo, Na., Tremblay, Gabriel., Piercy, James., Holbrook, Tim., Young, Benjamin. 2019. Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients. *Cost Effectiveness and Resource Allocation*, 17(26): 1-9, <https://doi.org/10.1186/s12962-019-0195-2>. [disitasi 12 Agustus 2023]
- Purba FD, Hunfeld JAM, Iskandarsyah A, Fitriana TS, Sadarjoen SS, Ramos-Goni JM, et al. 2017. The Indonesian EQ-5D-5L Value Set. *Pharmacoeconomics*. July; 35(11): 1153-1165, <https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/28695543/>. [disitasi 22 November 2022].
- Purwaningsih S.S W. 2008. Perkembangan HIV dan AIDS di Indonesia : Tinjauan sosiodemografis. *Jurnal Kependudukan Indonesia* III(2): 75 - 79. Available from : <https://ejournal.kependudukan.lipi.go.id/index.php/jki/article/view/170>. [disitasi 19 Oktober 2022].
- Rakasiwi, Kautsar. 2021. Pengaruh Faktor Demografi dan Sosial Ekonomi terhadap Status Kesehatan Individu di Indonesia. *Kajian Ekonomi Keuangan*. Agustus; 5(2): 146-157, <https://fiskal.kemenkeu.go.id/ejournal/>. [disitasi 06 Juni 2023].

- Restelli, U., Rizzardini, Giuliano., Antinori, Andrea., Lazzarin, Adriano., Bonfanti, Marzia., Bonfanti, Paolo., Croce, Davide. 2017. Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients. Dovepress, Therapeutics and Clinical Risk Management, Juni; Volume 13: 787-797, <http://dx.doi.org/10.2147/TCRM.S135972>. [disitasi 12 Agustus 2023]
- Reysa M. 2018. Self-stigma pada orang dengan HIV dan AIDS di Kota Makassar. Thesis, Departemen Ilmu komunikasi Fakultas ilmu sosial dan politik Universitas Hasanuddin. http://digilib.unhas.ac.id/uploaded_files/temporary/DigitalCollection/ZDc3NTI1NTNhNDZmNzc4NjQ4NmM5ODIwOTI2NjAyNDU1N2ViOTIyYQ==.pdf. [disitasi 15 Juni 2023].
- Riyarto, S. et al., Juli 2010. The financial burden of HIV care, including antiretroviral therapy, on patients in three sites in Indonesia. *Health Policy and Planning*, 25(4), pp. 272-282, <https://doi.org/10.1093/heapol/czq004>.
- Rokhani , Mustofa. 2018. Kualitas hidup ODHA setelah 10 tahun dengan HIV/AIDS. In: *Prosiding Seminar Nasional Universitas Muhammadiyah Semarang (Unimus)*. Semarang. p. 58-63.
- Rosen, S., Ketlhapile , M., Sanne, I. & Desilva, M., 2007. Cost to patients of obtaining treatment for HIV/AIDS in South Africa. *South African Medical Journal*, Volume 97, pp. 524-529, <http://www.ncbi.nlm.nih.gov/pubmed/17805455>.
- Rumah Sakit Universitas Airlangga. 2019. *Manajemen HIV/AIDS terkini, komprehensi dan multidisiplin*. 1st ed. Hidayati AN, Rosyid AN, Nugroho CWd, editors. Surabaya: Airlangga University Press.
- Setiawan D, Endarti D, Suwantika A. 2017. *Farmakoekonomi modelling*. 2nd ed. Setiawan D, editor. Purwokerto: UM Purwokerto Press.
- Siregar, A. Y. et al., 2015. Costs of HIV/AIDS treatment in Indonesia by time of treatment and stage of disease. *BMC Health Services Research*, 15(440), pp. 1-12, <https://doi.org/10.1186/s12913-015-1098-3>.
- Sutrasno MA, Yulia N, Rumana NA, Fannya P. 2019. Literature Review Gambaran Karakteristik Pasien HIV/AIDS di Fasilitas Pelayanan Kesehatan di Indonesia. *Jurnal Manajemen Informasi dan Administrasi Kesehatan*. ; 5(1): 50-59, https://digilib.esaunggul.ac.id/public/UEU-Journal-25541-11_2808.pdf. [disitasi 06 Juni 2023].
- The EuroQol Group. 2022. EQ-5D. <https://euroqol.org/>. [disitasi 14 Oktober 2022].

- The Joint United Nations Programme on HIV/AIDS (UNAIDS). 2000. AIDS and HIV infection information for United Nations employees and their families. 1st ed. Geneva.
- Tremblay, G., Chounta, Vasiliki., Piercy, James., Holbrook, Tim., Garib, Shan Ashton., Bukin, Evgeny K., Punekar, Yogesh Suresh. 2018. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1–Infected Treatment-Naive Patients in Russia. *Value in health regional* , Issue 16: 74-80, doi: 10.1016/j.vhri.2018.08.001. [disitasi 12 Agustus 2023]
- The Joint United Nations Programme on HIV/AIDS (UNAIDS). 2021. Country Factsheet Indonesia 2021—: HIV and AIDS estimates. <https://www.unaids.org/en/regionscountries/countries/indonesia>. [disitasi 17 Oktober 2022].
- Wilandika A. 2019. Penilaian Stigma Petugas Kesehatan Pada Orang Dengan HIV/AIDS (ODHA) Pada Salah Satu Puskesmas Di Bandung. *Jurnal Keperawatan*. Januari; 10(1): 7-14., <https://doi.org/10.22219/jk.v10i1.6321>. [disitasi 16 Juni 2023].
- World Health Organization (WHO). 2019. Policy brief : Update of recommendation on first and second line antiretroviral regimens. Geneva.
- World Health Organization (WHO). 2021. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring 2nd ed [Internet]. Geneva: World Health Organization. <https://www.who.int/publications/i/item/9789240031593>. [disitasi 22 September 2022].
- Wu AW. 2000. Quality of life assessment comes of age in the era of highly active antiretroviral therapy. *AIDS*. <https://doi.org/10.1097/00002030-200007070-00019>. [disitasi 10 November 2022].
- Yared, B., 2019. Cost-Effectiveness of Dolutegravir- Versus Efavirenz-Based First-Line Antiretroviral Treatments and Health-related Quality of Life of Adults with HIV/AIDS in Ethiopia. *Pharmaco-Epidemiology and Social Pharmacy*, Addis Abeba University, pp. Thesis, <http://etd.aau.edu.et/handle/123456789/26128>. [disitasi 12 Agustus 2023]
- Yaunin , Afriant , Hidayat. 2014. Kejadian Gangguan Depresi pada Penderita HIV/AIDS yang Mengunjungi Poli VCT RSUP Dr. M. Djamil Padang Periode Januari - September 2013. *Jurnal Kesehatan Andalas.*; 3(2), <http://jurnal.fk.unand.ac.id/index.php/jka/article/view/100/95>. [disitasi 08 Juni 2023].

- Yoopetch, P., dan Kemvaranan, C. 2019 . PP12 Cost-Utility Analysis Of Dolutegravir For HIV-1 Infection In Thailand. *International Journal of Technology Assessment in Health Care*, Desember; 35(S1): 39-40, DOI:10.1017/S0266462319001879. [disitasi 12 Agustus 2023]
- Yuliandra, Y., Nosa, U. S., R. & Almasdy, D., 2017. Terapi Antiretroviral pada Pasien HIV/AIDS di RSUP. Dr. M.Djamil Padang: Kajian Sociodemografi dan Evaluasi Obat. *Jurnal sains dan farmasi klinis*, 4(1), pp. 1-8, <http://jsfk.ffarmasi.unand.ac.id/index.php/jsfk/article/view/173>.
- Zachariah , R. et al., 2006. Acceptance of anti-retroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and associated with cost of transport. *PLoS One*, 1(1), p. e121, <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0000121>.
- Zhang Y, He C, Peasgood Td. 2022. Use of quality-of-life instruments for people living with HIV: a global systematic review and meta-analysis. *Journal of the International AIDS Society* Maret; 25:19, <https://doi.org/10.1002/jia2.25902>. [disitasi 17 Oktober 2022].
- Zhou T, Haijing G, Wang L, Zhang Y, Rui M, Ma A. 2021. Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review. *Frontier in Public Health*. Juni; 9(6): 1-23, <https://www.frontiersin.org/articles/10.3389/fpubh.2021.675523/full>. [disitasi 03 Juni 2023]

